Press Release: Virometix : Virometix Announces Completion of Initial Vaccination of the First Dose Cohort in Phase 1 Study with V-306

SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, announced today the completion of initial vaccination of the first dose cohort in the Phase 1 healthy volunteer study of V-306, its candidate vaccine for prophylaxis of RSV (Respiratory Syncytial Virus) infection in neonates. All 20 subjects received the first dos